Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

NCT ID: NCT02153762

Last Updated: 2017-04-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2014-01-31

Brief Summary

The purpose of this study is to evaluate the safety and tolerability, as well as effectiveness, with regards to the order of application for Locoid Lipocream and Hylatopic Plus cream in patients with atopic dermatitis (AD), which is a type of skin rash.Topical skin barrier repair therapies (BRT) that are plain moisturizing creams/lotions with added lipids (fats/oils), such as Hylatopic Plus cream, have emerged as an effective addition to the the treatment of atopic dermatitis. BRTs are often used along with topical steroids (medicated creams), such as Locoid lotion, on skin with AD, and as a monotherapy (single treatment) on both non-diseased and diseased skin. Since BRTs help to restore components of skin that are absent in skin with AD, it is believed that long-term BRT use may reduce further development of further AD. This is an open-label, single site study.

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Right side

Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.

Group Type: EXPERIMENTAL

Locoid Lipocream

Intervention Type: DRUG

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Hylatopic Plus

Intervention Type: DRUG

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Left first

Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.

Group Type: ACTIVE_COMPARATOR

Locoid Lipocream

Intervention Type: DRUG

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Hylatopic Plus

Intervention Type: DRUG

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Interventions

Locoid Lipocream

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Intervention Type: DRUG

Hylatopic Plus

Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.

Intervention Type: DRUG

Other Intervention Names

Topical skin barrier repair therapies (BRT); Topical skin barrier repair therapies (BRT)

Eligibility Criteria

Inclusion Criteria

• subjects of at least 3 months of age.
• clinical diagnosis of stable mild to moderate AD using the Hanifin and Rajka criteria for diagnosing AD
• AD lesions of similar size and severity of bilateral anatomic location
• a SPGA score of 2 or 3 and at least 10% BSA involvement at baseline
• in good health, without evidence of disease process(es) that would present patient safety concerns or confounding factors for assessment of study objectives
• able and willing to understand and sign an informed consent (or if applicable parent or legal guardian sign an informed consent),
• able and willing to agree to requirements and restrictions of the study
• Subjects who are willing to discontinue all systemic corticosteroids, immunomodulators, ultra violet light therapy or other medication (investigational or otherwise) that may have an effect on atopic dermatitis disease progression for 30 days prior to the baseline measurement.
• Subjects on a stable maintenance therapy (at least 30 days of use prior to baseline) of antihistamines and/or nasal spray containing corticosteroids for the treatment of bronchial asthma or allergic rhinitis, and antibiotics for the treatment of acne will be allowed.
• Subjects who are willing to discontinue use of topical treatments for AD including, but not limited to, corticosteroids, immunomodulators, vitamin D treatments, retinoids, topical antihistamines for at least 14 days prior to baseline
• Subjects who are willing to discontinue use of oral antibiotic therapy for at least 7 days prior to baseline, unless prescribed for acne treatment as previously described
• Subjects with no known allergy to any of the study product ingredients
• Women of childbearing potential must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.

Exclusion Criteria

• immunocompromised patients, or subjects with extensive disease that could not reasonably be controlled with topical therapy
• history or evidence of other conditions that would interfere with the evaluation of the study medication
• subjects desiring excessive or prolonged exposure to UV light (e.g. sunlight/tanning beds) during the study
• Use of topical medications for AD or any other medical condition.
• Subjects currently involved in another clinical research study.
• Subjects, who are pregnant, breast feeding or planning a pregnancy.
• Subjects with clinically significant unstable medical or mental disorders.
• Subjects who are unwilling or unable to comply with the requirements of the protocol.

• Minimum Eligible Age: 3 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joshua Zeichner, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Countries

United States

Other Identifiers

GCO 12-1932

Identifier Type: -

Identifier Source: org_study_id